Cargando…

IL-2 immunotherapy for targeting regulatory T cells in autoimmunity

FOXP3(+) regulatory T cells (T(reg)) are indispensable for immune homoeostasis and for the prevention of autoimmune diseases. Interleukin-2 (IL-2) signalling is critical in all aspects of T(reg) biology. Consequences of defective IL-2 signalling are insufficient numbers or dysfunction of T(reg) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lykhopiy, Valentina, Malviya, Vanshika, Humblet-Baron, Stephanie, Schlenner, Susan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575774/ https://www.ncbi.nlm.nih.gov/pubmed/37741949 http://dx.doi.org/10.1038/s41435-023-00221-y

Ejemplares similares

Targeting regulatory T cells for immunotherapy in melanoma
por: Huang, Lili, et al.
Publicado: (2021)

Validation of a multicolor staining to monitor (phospho)STAT5 levels in regulatory T-cell subsets
por: Ehx, Grégory, et al.
Publicado: (2015)

Targeted Immunotherapy for Autoimmune Disease
por: Jung, Seung Min, et al.
Publicado: (2022)

Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
por: Kim, Ji-Hae, et al.
Publicado: (2021)

Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders
por: Stanford, Stephanie M., et al.
Publicado: (2023)

IL-10-producing regulatory B cells (B10 cells) in autoimmune disease
por: Kalampokis, Ioannis, et al.
Publicado: (2013)

Increased IL‐10‐producing regulatory T cells are characteristic of severe cases of COVID‐19
por: Neumann, Julika, et al.
Publicado: (2020)

Mechanisms of Regulatory B cell Function in Autoimmune and Inflammatory Diseases beyond IL-10
por: Ray, Avijit, et al.
Publicado: (2017)

Follicular regulatory T cells: a novel target for immunotherapy?
por: Huang, Yao, et al.
Publicado: (2020)

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells
por: Ge, Xiaoxu, et al.
Publicado: (2019)

CTLA4-Ig Effectively Controls Clinical Deterioration and Immune Condition in a Murine Model of Foxp3 Deficiency
por: Gerbaux, Margaux, et al.
Publicado: (2023)

Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis
por: Ciano-Petersen, Nicolás Lundahl, et al.
Publicado: (2022)

IL-2 as a therapeutic target for the restoration of Foxp3(+ )regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease
por: d'Hennezel, Eva, et al.
Publicado: (2010)

Necroptosis in Immuno-Oncology and Cancer Immunotherapy
por: Sprooten, Jenny, et al.
Publicado: (2020)

Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells
por: Singh, Bhagirath, et al.
Publicado: (2013)

Smad3 binding to the foxp3 enhancer is dispensable for the development of regulatory T cells with the exception of the gut
por: Schlenner, Susan M., et al.
Publicado: (2012)

The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations
por: Terry, Lauren V., et al.
Publicado: (2020)

Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity
por: Zhang, Bo, et al.
Publicado: (2023)

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
por: Mei, Henrik E, et al.
Publicado: (2012)

Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity
por: Wang, Chun Jing, et al.
Publicado: (2022)

Regulatory cells and the effect of cancer immunotherapy
por: Iglesias-Escudero, María, et al.
Publicado: (2023)

Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
por: Huppler, Anna R, et al.
Publicado: (2012)

The regulatory mechanism and potential application of IL-23 in autoimmune diseases
por: Xiong, De-Kai, et al.
Publicado: (2022)

Prospects of IL-2 in Cancer Immunotherapy
por: Choudhry, Hani, et al.
Publicado: (2018)

Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
por: Yang, Ying, et al.
Publicado: (2020)

Regulatory NK cells in autoimmune disease
por: Bahadorian, Davood, et al.
Publicado: (2023)

Pregnancy and Tumour: The Parallels and Differences in Regulatory T Cells
por: Muralidhara, Prerana, et al.
Publicado: (2022)

Regulatory B cells in autoimmune rheumatic diseases
por: Sakkas, Lazaros I.
Publicado: (2017)

Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy
por: Siddiqui, Khalid, et al.
Publicado: (2023)

New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
por: Soler, Maria Florencia, et al.
Publicado: (2023)

Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies
por: Gastaldi, Matteo, et al.
Publicado: (2015)

Emerging immunotherapies for autoimmune kidney disease
por: Foster, Mary Helen, et al.
Publicado: (2019)

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2021)

Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease
por: Lohr, Jens, et al.
Publicado: (2006)

Antibody-based cancer immunotherapy by targeting regulatory T cells
por: Li, Quanxiao, et al.
Publicado: (2023)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

IL-12p35 induces expansion of IL-10 and IL-35-expressing regulatory B cells and ameliorates autoimmune disease
por: Dambuza, Ivy M., et al.
Publicado: (2017)

Regulatory B Cells Control T Cell Autoimmunity Through IL-21-Dependent Cognate Interactions
por: Yoshizaki, Ayumi, et al.
Publicado: (2012)

Evaluation of immune suppressive mechanisms in a murine model of familial hemophagocytic lymphohistiocytosis
por: Humblet-Baron, Stéphanie, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hgeso6tajdpnhfj3iq7v79hnpq